Latest Conference Articles

Gildeuretinol has also been evaluated in atrophic age-related macular degeneration, said Philip J. Ferrone, MD

The newest research findings create "tangible benchmarks" for how earlier treatment can lead to better outcomes, said Dr. Kim.

During the American Academy of Ophthalmology annual scientific meeting, the organization shared breaking news and updates from ongoing projects.

Dr. Singh reported that when technicians understand why they are performing a diagnostic test, they perform better and think critically in patient care situations.

AAO attendees can preview the new technician training platform on Sunday, October 19.

Data suggests the candidate can reduce the number of injections and treatment burden for patients

This year, 18 presenters will deliver named lectures during the American Academy of Ophthalmology meeting.

The video-driven platform will improve workflow, education and engagement, said Inder Paul Singh, MD.

The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life.

Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee.

Ultra-high-resolution OCT advances retinal imaging, enabling detailed visualization of disease progression and potential therapeutic effects in eye conditions.

The Phase 1/2 ArMaDa trial is evaluating OCU410 (Ocugen), a gene therapy candidate for patients with dry age-related macular degeneration.

The Eye Care Network spoke with Sebastian Wolf, MD, PhD, and Sophie Bonnin, MD, PhD, who presented new findings from the OCS-05 phase 2 ACUITY trial.

Hear highlights from the Vit-Buckle Society and its presence at EURETINA 2025.

ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research and fostering global networking among retina specialists.

Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space.

The ultimate goal of redefining endpoints is enabling earlier diagnosis and treatment, said Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

At the EURETINA congress, Prof Pollreisz shared his contemporary approach to multimodal imaging in patients with diabetes.

During the EURETINA session, Stela Vujosevic, MD, PhD, FEBO, posed questions about the current staging for diabetic macular edema and diabetic retinopathy.

At the EURETINA meeting, Professor Uy described the ways artificial intelligence can augment an existing imaging workflow.

The EURETINA YOURS program prepares retina specialists for the EBO exam and helps them find training in the competitive subspecialty of vitreoretinal surgery.

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa.